As gene-editing technology moves from the research lab to the clinic, one of the biggest hurdles is effectively delivering the large and sensitive molecular components of the therapies to their intended targets. Stephen Burgess, Ph.D., of Croda Pharma discusses how lipid-based nanoparticles present promising solutions to these challenges.
.svg)
